Altimmune leads obesity drug developers lower after data for lead asset [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
Altimmune leads obesity drug developers lower after data for lead assetMar. 21, 2023 2:58 PM ETAltimmune, Inc. (ALT)AMGNPFENVOLLYVKTXRYTMBy:Dulan LokuwithanaSA News Editor5 Commentsmphillips007Leading weight loss drug developers are on the decline after clinical-stage biotech Altimmune (NASDAQ:50% lowerCiting topline data, Altimmune () said that pemvidutide, a GLP-1/glucagon dual receptor agonist, led to 10% or more weight loss in ~50% of subjects in its 48-week MOMENTUMPhase 2 obesity trial.Its Phase 1b trial for pemvidutide in patients with type 2 diabetes has indicated that the experimental therapy at 2.4 mg led to a 7.7% weight loss over 12 weeks, while patients on placebo experienced a mean weight gain of 0.8%.While Altimmune (Meanwhile, Viking Therapeutics (lost ~17%Pharma giants Eli Lilly (However, Novo Nordisk (According to Morgan Stanley, the market for anti-obesity drugs couldreach $54B by 2030
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking (VKTX) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead [Seeking Alpha]Seeking Alpha
- Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024PR Newswire
- Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- What Makes Viking Therapeutics (VKTX) an Attractive Potential Opportunity? [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 2/7/24 - In-Line
VKTX
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- VKTX's page on the SEC website